Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 9/20 | 0.47 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10505548 | 0.89 | TYMS (0.46) | PNPTYMSHPRT1XDH | |
| SCHEMBL10506793 | 0.88 | TYMS (0.40) | PNPTYMSHPRT1XDH | |
| SCHEMBL10510230 | 0.88 | TYMS (0.46) | PNPTYMSNOS1HPRT1 | |
| SCHEMBL10385954 | 0.87 | PNP (0.44) | PNPHPRT1 | |
| SCHEMBL2128394 | 0.86 | HPRT1 (0.49) | PNPTYMSNOS1HPRT1QTRT1 | |
| SCHEMBL10507792 | 0.84 | TYMS (0.50) | PNPTYMSHPRT1QTRT1XDH | |
| SCHEMBL10508808 | 0.84 | HPRT1 (0.38) | PNPTYMSNOS1HPRT1 | |
| SCHEMBL10506525 | 0.83 | MTNR1A (0.47) | PNPTYMSXDH | |
| SCHEMBL10644971 | 0.83 | HPRT1 (0.38) | PNPTYMSNOS1HPRT1 | |
| SCHEMBL10915999 | 0.83 | PNP (0.43) | PNPNOS1HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0374096-B1 | COMBINATION THERAPY INVOLVING 2',3'-DIDEOXYPURINE NUCLEOSIDE AND AN INHIBITOR OF PURINE NUCLEOSIDE PHOSPHORYLASE, AND ITS COMPOSITIONS | CIBA-GEIGY AG (CH) | 1992-12-02 | — | — | EP | claimed |
| JP-2204414-A | — | — | None | — | — | JP | disclosed |
| US-20220211710-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH NUCLEOSIDE-METABOLISM MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-07 | — | — | US | disclosed |
| WO-2021022105-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH NUCLEOSIDE-METABOLISM MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-0550574-A1 | HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992005180-A1 | HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
| US-5051429-A | For treatment of autoimmune diseases such as arthritis, lupus, antiinflammatory agents, multiple sclerosis, diabetes and viral diseases | WARNER-LAMBERT CO. (US) | 1991-09-24 | — | — | US | disclosed |
| US-4952693-A | TREATING AUTOIMMUNE DISEASES | WARNER-LAMBERT COMPANY (US) | 1990-08-28 | — | — | US | disclosed |
| JP-H02204414-A | COMBINATIONAL THERAPY USING 2',3'-DIDEOXYPURINENUCLEOSIDE/ PURINENUCLEOSIDE PHOSPHORYLASE INHIBITOR AND COMPOSITION | CIBA GEIGY AG | 1990-08-14 | — | — | JP | disclosed |
| US-4874862-A | Process for preparing guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| EP-0156559-B1 | 8-SUBSTITUTED GUANINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4772606-A | AUTOIMMUNE DISEASES, ORGAN TRANSPLANTS | WARNER-LAMBERT COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| US-4748177-A | Guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1988-05-31 | — | — | US | disclosed |
| EP-0178178-A2 | Purine derivatives | WARNER-LAMBERT COMPANY (US) | 1986-04-16 | — | — | EP | disclosed |
| EP-0156559-A2 | 8-Substituted guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1985-10-02 | — | — | EP | disclosed |